Page 11 - Layout 1

Strength of Evidence Low Low Low Low Insufficient Low Low Insufficient

Effect Estimate range 0.90-1.20) †† OR = 0.70 (0.50, 0.98) OR = 0.04 (0.01, 0.23) OR = 0.10 (0.03, 0.32) MD = 7.20 (4.10, 10.30) MD = 6.20-7.50 (lower CI range 0.79-4.94, upper CI range 10.06-11.61)†† MD = 5.50 (2.28, 8.72) MD = 25.30 (16.77, 33.83) N/A

Table B. SQ terbutaline pump versus comparator: Strength of evidence

Comparator Oral tocolytics No treatment Oral terbutaline Oral nifedipine Oral nifedipine Oral tocolytics No treatment N/A

for populations of interest (continued)

Population of Interest Singleton gestation L + RPT Singleton gestation Singleton/Multiple gestation + RPTL Twin gestation + RPTL Singleton gestation + RPTL Singleton gestation + RPTL Singleton gestation + RPTL N/A No events occurred in the SQ terbutaline pump group or in the two comparator groups. We did not grade this evidence here

Total Number of Events 318 50 38 N/A N/A N/A N/A N/A BPD = bronchopulmonary dysplasia; IVH = intraventricular hemorrhage; MD = mean difference; N/A = not applicable; OR = odds ratio; RPTL = recurrent preterm † One RCT reported significant intraventricular hemorrhage.10 No events were observed in pump or comparator groups. We did not grade this evidence here because it ‡ Incidence of delivery < 34 weeks was reported in one RCT, which showed a nonsignific

Number of Participants 558 60 64 656 1650 558 60 0 0.32, 2.87). We did not grade this evidence here because it did not pertain to any of the subgroups if interest. CI: 0.49, 5.02). We did not grade this evidence here because it did not pertain to any of the subgroups of interest. †† Studies were not pooled. Also, there was risk of double-counting of participants across these studies.

Number of Studies 1 18 1 13 1 20 1 16 2 15,17 1 18 1 13 0 labor; withdrawal-AE = withdrawal due to adverse effects because it did not pertain to any of the subgroups of interest.

Other Surrogate Outcomes (KQ2): Incidence of delivery < 37 weeks§ Other Surrogate Outcomes (KQ2): Mean prolongation of pregnancy (days)** Maternal Harms (KQ3): * One RCT also reported neonatal death. 11 did not pertain to any of the subgroups of interest. any of the subgroups of interest.

Outcome (continued) Withdrawal-AE

11